PHAR 株価推移チャート
PHAR 収入
Pharming Group N.V.
$16.49
-2.54%
$-0.43
本日現在の状況：Apr 28, 11:59:30 GMT-4
戻る
Pharming Group N.V. (PHAR) 収入
最新の利益結果: Q4 '25
報告済み: 2026-03-12
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
PHARの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Pharming Group N.V. PHARの前四半期の収益はどうでしたか？
Pharming Group N.V.の収益見積もりはいくらですか？
Pharming Group N.V.の収益品質スコアはどれくらいですか？
Pharming Group N.V.はいつ収益を報告しますか？
Pharming Group N.V.の予想収益はいくらですか？
Pharming Group N.V.は収益予想を上回りましたか？
主要データ
前終値
$16.92
始値
$16.41
当日レンジ
$16.41 - $16.49
52週レンジ
$8.39 - $21.34
取引高
763
平均取引高
24.7K
配当利回り
--
1株当たり利益(TTM)
0.04
時価総額
$1.1B
Pharming Group N.V.とは何ですか？
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.